

# Primary biliary cirrhosis

Hepatology

50, 291-308

DOI: [10.1002/hep.22906](https://doi.org/10.1002/hep.22906)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. <i>Hepatology</i> , 2009, 50, 1884-1892.	3.6	114
2	Toward the molecular dissection of primary biliary cirrhosis. <i>Hepatology</i> , 2009, 50, 1347-1350.	3.6	10
3	Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. <i>Journal of Hepatology</i> , 2009, 51, 1084-1085.	1.8	15
4	Ursodeoxycholic acid in primary biliary cirrhosis: Reply. <i>Journal of Hepatology</i> , 2009, 51, 1085-1086.	1.8	28
8	Liver disease in women: Examining prevalence and complications. <i>Gastrointestinal Nursing</i> , 2010, 8, 30-37.	0.0	2
9	Stigma and Liver Disease. <i>Illness Crisis and Loss</i> , 2010, 18, 229-255.	0.4	15
10	Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Current Gastroenterology Reports</i> , 2010, 12, 13-22.	1.1	24
11	Autoantibodies as Prognostic Markers in Autoimmune Liver Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2144-2161.	1.1	72
12	Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3207-3217.	1.1	27
13	Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: Another step forward. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 239-241.	0.9	1
14	Extrahepatic conditions associated with primary biliary cirrhosis. <i>Hepatology</i> , 2010, 51, 713-713.	3.6	1
15	Diagnosis and management of primary sclerosing cholangitis. <i>Hepatology</i> , 2010, 51, 660-678.	3.6	1,048
16	Biliary physiology and disease: Reflections of a physician-scientist. <i>Hepatology</i> , 2010, 51, 1095-1106.	3.6	26
18	The specificity of fatigue in primary biliary cirrhosis: Evaluation of a large clinic practice. <i>Hepatology</i> , 2010, 52, 562-570.	3.6	46
19	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010, 52, 472-479.	3.6	267
20	Non-neoplastic diseases of the intra- and extrahepatic bile ducts. <i>Diagnostic Histopathology</i> , 2010, 16, 380-387.	0.2	0
21	Primary biliary cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 647-654.	1.0	32
22	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 655-657.	9.4	205

#	ARTICLE	IF	CITATIONS
23	Pharmacotherapy of cholestatic liver diseases. <i>Journal of Digestive Diseases</i> , 2010, 11, 119-125.	0.7	18
25	Validation of Coding Algorithms for the Identification of Patients with Primary Biliary Cirrhosis Using Administrative Data. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 175-182.	1.8	17
26	Hepatocyte Death: A Clear and Present Danger. <i>Physiological Reviews</i> , 2010, 90, 1165-1194.	13.1	399
27	Cholestatic Pruritus: Colesevelam. <i>Hospital Pharmacy</i> , 2010, 45, 914-915.	0.4	0
28	PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 125-131.	0.2	69
29	Cholestatic Pruritus: Sertraline (Adults). <i>Hospital Pharmacy</i> , 2010, 45, 768-770.	0.4	0
30	Treatment options for primary sclerosing cholangitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 473-488.	1.4	16
31	Innovative Management of Pruritus. <i>Dermatologic Clinics</i> , 2010, 28, 467-478.	1.0	26
32	Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2010, 42, 911-912.	0.4	22
33	Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. <i>Translational Research</i> , 2010, 155, 120-122.	2.2	2
34	Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches. <i>Gastroenterology</i> , 2010, 139, 1481-1496.	0.6	222
35	A2BP1 as a novel susceptible gene for primary biliary cirrhosis in Japanese patients. <i>Human Immunology</i> , 2010, 71, 520-524.	1.2	18
36	Primary biliary cirrhosis: A 2010 update. <i>Journal of Hepatology</i> , 2010, 52, 745-758.	1.8	251
37	Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. <i>Journal of Hepatology</i> , 2010, 53, 307-312.	1.8	104
38	Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. <i>Journal of Hepatology</i> , 2010, 53, 537-541.	1.8	38
39	MARS: The ultimate warrior against pruritus of cholestasis?. <i>Journal of Hepatology</i> , 2010, 53, 228-229.	1.8	2
40	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
43	Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 387-392.	0.9	14

#	ARTICLE	IF	CITATIONS
44	Primary sclerosing cholangitis: overview and update. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 611-619.	8.2	49
47	Model for End-Stage Liver Disease Score Predicts Outcome in Cirrhotic Patients During Pregnancy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 694-699.	2.4	106
48	Prevalence of Primary Biliary Cirrhosisâ€“Autoimmune Hepatitis Overlap Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 609-612.	2.4	52
49	The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 29-33.	0.7	19
50	Pathophysiology and current management of pruritus in liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 89-97.	0.7	90
51	Disease-specific autoantibodies in primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2011, 412, 502-512.	0.5	86
52	Diagnostic criteria for autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 665-671.	1.0	22
53	Diagnosis of primary biliary cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 701-712.	1.0	29
54	A possible involvement of p62/sequestosomeâ€“1 in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis. <i>Liver International</i> , 2012, 32, 487-499.	1.9	45
55	Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. <i>Journal of Hepatology</i> , 2011, 54, 340-347.	1.8	85
56	Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. <i>Journal of Hepatology</i> , 2011, 54, 374-385.	1.8	470
57	Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. <i>Journal of Hepatology</i> , 2011, 55, 1361-1367.	1.8	353
58	A major step towards effective treatment evaluation in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 1178-1180.	1.8	12
59	The Itch of Liver Disease. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, 93-98.	1.6	42
60	Primary Biliary Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 373-386.	1.0	18
61	Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2011, 41, 358-363.	1.8	10
62	Detection of Dâ€“3â€“phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation. <i>Hepatology Research</i> , 2011, 41, 867-876.	1.8	5
63	Primary biliary cirrhosis â€“ Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nationâ€“wide retrospective study in Japan. <i>Hepatology Research</i> , 2011, 41, 877-886.	1.8	40

#	ARTICLE	IF	CITATIONS
64	Primary biliary cirrhosis. <i>Lancet</i> , The, 2011, 377, 1600-1609.	6.3	294
65	The diagnosis and treatment of primary biliary cirrhosis. <i>The Korean Journal of Hepatology</i> , 2011, 17, 173.	1.5	19
66	Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2011, 46, 200.	0.7	4
67	Varices in Early Histological Stage Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e66-e71.	1.1	40
68	Parenteral Bisphosphonates for Osteoporosis in Patients With Primary Biliary Cirrhosis. <i>American Journal of Therapeutics</i> , 2011, 18, 375-381.	0.5	16
70	Genetic association of <i>FCRL3</i> polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. <i>Tissue Antigens</i> , 2011, 77, 239-243.	1.0	21
71	Replicated association of <i>HLA-DQA1</i> with susceptibility of primary biliary cirrhosis in a Japanese cohort. <i>Tissue Antigens</i> , 2011, 78, 65-68.	1.0	31
72	No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1345-1346.	1.4	7
73	Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 235-242.	1.9	153
74	Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. <i>Clinical and Experimental Immunology</i> , 2011, 163, 147-156.	1.1	42
75	A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. <i>Liver International</i> , 2011, 31, 361-368.	1.9	62
76	The impact of biopsychosocial factors on quality of life: Women with primary biliary cirrhosis on waiting list and post liver transplantation. <i>British Journal of Health Psychology</i> , 2011, 16, 502-527.	1.9	15
77	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. <i>Digestive Diseases and Sciences</i> , 2011, 56, 578-585.	1.1	66
78	Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 545-554.	1.1	70
79	Prognostic Factors and Survival Analysis of Antimitochondrial Antibody-Positive Primary Biliary Cirrhosis in Chinese Patients. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2750-2757.	1.1	11
80	Hepatobiliary Complications of Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2011, 13, 495-505.	1.1	16
81	Autoimmune liver disease - are there spectra that we do not know?. <i>Comparative Hepatology</i> , 2011, 10, 9.	0.9	11
82	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. <i>Immunity and Ageing</i> , 2011, 8, 12.	1.8	25

#	ARTICLE	IF	CITATIONS
83	Human leukocyte antigen in primary biliary cirrhosis: An old story now reviving. <i>Hepatology</i> , 2011, 54, 714-723.	3.6	74
84	Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome developing in a patient with systemic lupus erythematosus: a case report and review of the literature. <i>Lupus</i> , 2011, 20, 108-111.	0.8	13
85	Multiple Autoimmune Propensity and B-Non-Hodgkin Lymphoma: Cause or Effect?. <i>Autoimmune Diseases</i> , 2011, 2011, 1-5.	2.7	1
86	Primary Biliary Cirrhosis: Family Stories. <i>Autoimmune Diseases</i> , 2011, 2011, 1-11.	2.7	34
87	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	1.4	139
88	Sex Differences Associated with Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	37
89	The use of plasmapheresis in managing primary biliary cirrhosis presenting with profound hypercholesterolaemia. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 156-158.	0.6	2
90	Liver immunology. , 2012, , 153-165.e2.		0
91	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. <i>Genes and Immunity</i> , 2012, 13, 328-335.	2.2	78
92	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-10.	0.2	2
93	Rheumatoid Arthritis and Primary Biliary Cirrhosis: Cause, Consequence, or Coincidence?. <i>Arthritis</i> , 2012, 2012, 1-7.	2.0	21
94	Twelve-Year-Old Girl with Primary Biliary Cirrhosis. <i>Case Reports in Pediatrics</i> , 2012, 2012, 1-3.	0.2	6
95	Natural history and management of primary biliary cirrhosis. <i>Hepatic Medicine: Evidence and Research</i> , 2012, 4, 61.	0.9	11
96	Inflammatory myopathies associated with anti-mitochondrial antibodies. <i>Brain</i> , 2012, 135, 1767-1777.	3.7	95
97	Clinical Guideline of Primary Biliary Cirrhosis 2012 The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. <i>Acta Hepatologica Japonica</i> , 2012, 53, 633-686.	0.0	6
98	The epidemiology and natural history of primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 824-830.	0.8	61
99	The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 155-161.	1.1	61
100	Chlorambucil for patients with primary biliary cirrhosis. <i>The Cochrane Library</i> , 2012, , CD008714.	1.5	4

#	ARTICLE	IF	CITATIONS
101	A Case of IgG4-related Sclerosing Cholangitis Overlapped with Primary Biliary Cirrhosis. <i>Internal Medicine</i> , 2012, 51, 1695-1699.	0.3	11
104	Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis. <i>Hepatology</i> , 2012, 56, 1409-1417.	3.6	94
105	The immunopathology of liver granulomas in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2012, 39, 216-221.	3.0	48
106	Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. <i>Autoimmunity Highlights</i> , 2012, 3, 105-112.	3.9	7
107	Popular and unpopular infectious agents linked to primary biliary cirrhosis. <i>Autoimmunity Highlights</i> , 2012, 3, 95-104.	3.9	4
108	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012, 3, 127-132.	3.9	4
109	Prevalence and Mechanisms of Malnutrition in Patients With Advanced Liver Disease, and Nutrition Management Strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 117-125.	2.4	270
110	Pruritus in Chronic Cholestatic Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, 331-346.	1.0	58
111	Liver Disease in Pregnancy. <i>Clinics in Liver Disease</i> , 2012, 16, 247-269.	1.0	18
112	ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study. <i>Journal of Ultrasound</i> , 2012, 15, 226-231.	0.7	23
113	Levercirrose. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2012, 28, 43-52.	0.0	0
114	Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. <i>Liver International</i> , 2012, 32, 790-795.	1.9	62
115	Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. <i>Journal of Hepatology</i> , 2012, 57, 133-140.	1.8	97
116	Cholestasis-induced pruritus treated with ultraviolet B phototherapy: An observational case series study. <i>Journal of Hepatology</i> , 2012, 57, 637-641.	1.8	50
117	Primary biliary cirrhosis and Sjögren's syndrome: Autoimmune epithelitis. <i>Journal of Autoimmunity</i> , 2012, 39, 34-42.	3.0	118
118	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , 2012, 12, 92.	0.8	24
119	The Overlap Syndromes of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 58, 326-43.	1.1	62
120	Answers to Multiple Choice Questions. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 401-406.	0.4	0

#	ARTICLE	IF	CITATIONS
121	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. <i>American Journal of Human Genetics</i> , 2012, 91, 721-728.	2.6	251
122	Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 110-121.	0.7	42
123	Liver biopsy is a superior diagnostic method in some patients showing the typical laboratory features of autoimmune hepatitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 185-188.	0.7	6
124	What Is New in Primary Biliary Cirrhosis?. <i>Digestive Diseases</i> , 2012, 30, 20-31.	0.8	15
125	The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 230-241.	2.9	28
126	Complete spectrum of AMA-M2 positive liver disease in north India. <i>Hepatology International</i> , 2012, 6, 790-795.	1.9	3
127	Current pharmacotherapy for cholestatic liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2473-2484.	0.9	26
128	Primary biliary cirrhosis and bile acids. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, S13-S20.	0.7	25
129	Granulomatous Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, 387-396.	1.0	28
130	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2012, 11, 7-14.	0.6	36
131	Overlap Syndromes. , 2012, , 782-789.		0
132	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 1495-1506.	3.6	35
133	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 198-208.	3.6	277
134	Overcoming a "Probable" Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 288-297.	2.9	70
135	Autoimmunity and Environment: Am I at risk?. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 199-212.	2.9	60
136	Immunological diseases of the pancreatobiliary system: update on etiopathogenesis and cross-sectional imaging findings. <i>Abdominal Imaging</i> , 2012, 37, 261-274.	2.0	6
137	"Outpatient" albumin dialysis for cholestatic patients with intractable pruritus. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 696-704.	1.9	42
138	Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. <i>Journal of Digestive Diseases</i> , 2012, 13, 219-224.	0.7	51



#	ARTICLE	IF	CITATIONS
139	Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1443-1450.	1.9	27
140	Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 826-827.	1.1	16
141	Pathogenesis and management of pruritus in cholestatic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1150-1158.	1.4	50
142	Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1159-1166.	1.4	18
143	Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 506-511.	3.6	73
144	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. <i>Hepatology</i> , 2012, 55, 512-521.	3.6	130
145	Vitamin D Deficiency in Patients with Chronic Liver Disease and Cirrhosis. <i>Current Gastroenterology Reports</i> , 2012, 14, 67-73.	1.1	55
146	Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. <i>Autoimmunity Highlights</i> , 2013, 4, 1-9.	3.9	16
147	AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. <i>Hepatology</i> , 2013, 58, 2142-2152.	3.6	54
148	Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model. <i>BMC Gastroenterology</i> , 2013, 13, 64.	0.8	6
149	Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. <i>Hepatology International</i> , 2013, 7, 775-784.	1.9	22
150	Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. <i>Journal of Gastroenterology</i> , 2013, 48, 1160-1170.	2.3	26
151	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 343-364.	1.9	50
152	Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 405-410.	0.7	7
153	Liver transplantation and autoimmune liver diseases. <i>Liver Transplantation</i> , 2013, 19, 1065-1077.	1.3	83
154	A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 85-92.	1.4	153
155	Apoptosis and innate immune system: Novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013, 45, 630-636.	0.4	24
156	Not All PBC Is the Same!. <i>Gastroenterology</i> , 2013, 144, 494-497.	0.6	5

#	ARTICLE	IF	CITATIONS
157	Primary biliary cirrhosis: Is there still a place for histological evaluation?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 556-558.	0.7	5
158	Analysis of altered <sc>microRNA</sc> expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 543-550.	1.4	38
160	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 572-585.	0.7	54
161	Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 794-803.	1.9	14
162	High Levels of FCÎ³R3A and PRF1 Expression in Peripheral Blood Mononuclear Cells from Patients with Primary Biliary Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 458-464.	1.1	2
163	Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29â€¥year cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1354-1364.	1.9	32
164	The dynamic biliary epithelia: Molecules, pathways, and disease. <i>Journal of Hepatology</i> , 2013, 58, 575-582.	1.8	130
166	Association analysis of toll-like receptor 4 polymorphisms in Japanese primary biliary cirrhosis. <i>Human Immunology</i> , 2013, 74, 219-222.	1.2	6
167	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 46, 81-87.	3.0	64
168	A validated clinical tool for the prediction of varices in PBC: The Newcastle Varices in PBC Score. <i>Journal of Hepatology</i> , 2013, 59, 327-335.	1.8	31
169	Liver Transplant for Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2013, 17, 345-359.	1.0	20
170	Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: Whatâ€™s New?. <i>Current Infectious Disease Reports</i> , 2013, 15, 14-24.	1.3	22
171	Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. <i>Liver International</i> , 2013, 33, 312-320.	1.9	58
172	Î²1 integrin is a long-sought sensor for tauroursodeoxycholic acid. <i>Hepatology</i> , 2013, 57, 867-869.	3.6	8
173	Gutâ€™liver axis: an immune link between celiac disease and primary biliary cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 253-261.	1.4	39
174	Cholestatic Liver Disease Overlap Syndromes. <i>Clinics in Liver Disease</i> , 2013, 17, 243-253.	1.0	8
175	Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2013, 17, 229-242.	1.0	27
176	The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 303-330.	9.6	264

#	ARTICLE	IF	CITATIONS
177	Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. <i>Clinical and Experimental Immunology</i> , 2013, 172, 95-103.	1.1	25
178	B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid. <i>American Journal of Gastroenterology</i> , 2013, 108, 933-941.	0.2	102
179	A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 465-469.	0.4	0
180	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab. <i>Case Reports in Gastroenterology</i> , 2013, 7, 195-201.	0.3	14
181	Mouse model of primary biliary cirrhosis with progressive fibrosis: Are we there yet?. <i>Hepatology</i> , 2013, 57, 429-431.	3.6	10
182	Treatment of autoimmune liver disease: current and future therapeutic options. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 119-141.	1.1	40
183	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013, 14, 179-186.	2.2	52
184	Red blood cell distribution width is a potential prognostic index for liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1403-8.	1.4	95
185	Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 231-236.	0.8	5
186	Anti-mitochondrial antibody: Potential marker of myositis with chronic clinical course, muscle atrophy, cardiac involvement and granulomatous inflammation in muscle biopsy. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 18-18.	0.5	0
187	Tired of Being Tired. <i>Journal of Women's Health</i> , 2013, 22, 289-290.	1.5	0
188	Keratin 19 demonstration of canal of hering loss in primary biliary cirrhosis: "Minimal Change PBC". <i>Hepatology</i> , 2013, 57, 700-707.	3.6	34
189	Primary Biliary Cirrhosis is More Severe in Overweight Patients. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, e28-e32.	1.1	38
191	Connective tissue diseases in primary biliary cirrhosis: A population-based cohort study. <i>World Journal of Gastroenterology</i> , 2013, 19, 5131.	1.4	58
192	Distinct MicroRNAs Expression Profile in Primary Biliary Cirrhosis and Evaluation of miR 505-3p and miR197-3p as Novel Biomarkers. <i>PLoS ONE</i> , 2013, 8, e66086.	1.1	77
193	Hepatocellular carcinoma that arose from primary Sjögren's syndrome. <i>Annals of Hepatology</i> , 2013, 12, 824-829.	0.6	3
194	Serum MicroRNAs as Potential Biomarkers of Primary Biliary Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e111424.	1.1	63
196	Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 759-762.	0.8	17

#	ARTICLE	IF	CITATIONS
197	Predicting outcome in primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2014, 13, 316-326.	0.6	41
198	Autoimmune liver disorders and small-vessel vasculitis: four case reports and review of the literature. <i>Annals of Hepatology</i> , 2014, 13, 136-141.	0.6	11
199	Guidelines for the management of primary biliary cirrhosis. <i>Hepatology Research</i> , 2014, 44, 71-90.	1.8	93
200	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1351-1358.	0.5	3
201	Shear Wave Elastography for Liver Stiffness Measurement in Clinical Sonographic Examinations. <i>Journal of Ultrasound in Medicine</i> , 2014, 33, 437-447.	0.8	85
202	The Association between Bile Salt Export Pump Single-Nucleotide Polymorphisms and Primary Biliary Cirrhosis Susceptibility and Ursodeoxycholic Acid Response. <i>Disease Markers</i> , 2014, 2014, 1-6.	0.6	4
203	Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. <i>Biomedical Reports</i> , 2014, 2, 633-636.	0.9	89
204	Pathologies h�patiques. , 2014, , 111-139.		0
205	STAT4Gene Polymorphisms Are Associated with Susceptibility and ANA Status in Primary Biliary Cirrhosis. <i>Disease Markers</i> , 2014, 2014, 1-8.	0.6	15
206	AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 1443-1445.	1.8	32
207	Changing epidemiology and natural history of primary biliary cirrhosis. <i>Clinical Liver Disease</i> , 2014, 3, 12-14.	1.0	3
208	Autophagy "another piece of the puzzle towards understanding primary biliary cirrhosis?. <i>Liver International</i> , 2014, 34, 481-483.	1.9	7
209	Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. <i>Hepatology</i> , 2014, 60, 1708-1716.	3.6	67
210	Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?. <i>Clinical Liver Disease</i> , 2014, 3, 29-33.	1.0	9
211	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
212	Overlap syndrome: A real syndrome?. <i>Clinical Liver Disease</i> , 2014, 3, 43-47.	1.0	8
213	Editorial for "Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis". <i>Liver International</i> , 2014, 34, 328-329.	1.9	1
214	Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 706-715.	1.4	14

#	ARTICLE	IF	CITATIONS
215	Evaluation of nail fold capillaroscopy findings in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2014, 44, E129-36.	1.8	6
216	Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 282-301.	1.9	75
217	Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. <i>Liver International</i> , 2014, 34, 220-226.	1.9	16
218	Advances in Pathogenesis and Management of Pruritus in Cholestasis. <i>Digestive Diseases</i> , 2014, 32, 637-645.	0.8	58
219	Evidence-Based Treatment of Primary Biliary Cirrhosis. <i>Digestive Diseases</i> , 2014, 32, 626-630.	0.8	5
220	Diagnosis and management of primary biliary cirrhosis. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1667-1678.	1.3	20
221	Monitoring and Care. , 2014, , 478-493.		0
222	Fibrate treatment for primary biliary cirrhosis. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 279-286.	1.0	36
223	Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 532-537.	0.8	25
224	Primary biliary cirrhosis in 2014. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 245-252.	1.0	24
225	Treatment of primary biliary cirrhosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 11-25.	0.5	0
226	The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. <i>Medical Molecular Morphology</i> , 2014, 47, 162-168.	0.4	12
227	Pathogenesis of Bile Duct Lesions in Primary Biliary Cirrhosis. , 2014, , 293-303.		1
228	The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1533-42.	1.4	47
229	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. <i>Pharmaceuticals</i> , 2014, 7, 18-28.	1.7	1
230	Primary biliary cirrhosis“autoimmune hepatitis overlap syndrome: Simplified criteria may be effective in the diagnosis in Chinese patients. <i>Journal of Digestive Diseases</i> , 2014, 15, 660-668.	0.7	14
231	Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. <i>Liver International</i> , 2014, 34, 197-203.	1.9	94
232	Progressive multifocal leukoencephalopathy in a patient with pre-clinical primary biliary cirrhosis. <i>Clinical Neurology and Neurosurgery</i> , 2014, 123, 45-49.	0.6	6

#	ARTICLE	IF	CITATIONS
233	Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study. <i>Clinical Radiology</i> , 2014, 69, 836-840.	0.5	25
234	Receptors, cells and circuits involved in pruritus of systemic disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 869-892.	1.8	82
235	Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. <i>Journal of Gastroenterology</i> , 2014, 49, 332-342.	2.3	21
236	Concurrent autoimmune pancreatitis and primary Biliary cirrhosis: a rare case report and literature review. <i>BMC Gastroenterology</i> , 2014, 14, 10.	0.8	5
237	Aquaporin-1 is associated with arterial capillary proliferation and hepatic sinusoidal transformation contributing to portal hypertension in primary biliary cirrhosis. <i>Medical Molecular Morphology</i> , 2014, 47, 90-99.	0.4	3
238	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2014, 60, 931-940.	3.6	99
239	Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation. <i>Clinical Liver Disease</i> , 2014, 3, 90-92.	1.0	2
240	Cholestatic Phenotypes of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1430-1438.	2.4	55
241	Factors Associated With Response to Therapy and Outcome of Patients With Primary Biliary Cirrhosis With Features of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 863-869.	2.4	64
242	Bile acids reach out to the spinal cord: New insights to the pathogenesis of itch and analgesia in cholestatic liver disease. <i>Hepatology</i> , 2014, 59, 1638-1641.	3.6	18
243	New therapeutics in primary biliary cirrhosis: will there ever be light?. <i>Liver International</i> , 2014, 34, 167-170.	1.9	8
244	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	1.6	20
245	Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with UDCA-Resistant Primary Biliary Cirrhosis. <i>Stem Cells and Development</i> , 2014, 23, 2482-2489.	1.1	69
246	Autoantibodies in pre-clinical autoimmune disease. <i>Clinica Chimica Acta</i> , 2014, 437, 14-18.	0.5	37
247	Immunologic derangement preceding clinical autoimmunity. <i>Lupus</i> , 2014, 23, 1305-1308.	0.8	4
248	Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1414-1420.	2.3	35
249	Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis. <i>Clinical and Experimental Medicine</i> , 2014, 14, 409-416.	1.9	7
250	The diagnosis of primary biliary cirrhosis. <i>Autoimmunity Reviews</i> , 2014, 13, 441-444.	2.5	133

#	ARTICLE	IF	CITATIONS
251	Extrahepatic Platelet-Derived Growth Factor- $\beta$ , Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice. <i>Gastroenterology</i> , 2014, 147, 1378-1392.	0.6	127
252	Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. <i>Journal of Hepatology</i> , 2014, 60, 160-166.	1.8	44
253	Good Maternal and Fetal Outcomes for Pregnant Women With Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1179-1185.e1.	2.4	56
255	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , 2014, 60, 1249-1258.	1.8	113
256	Reduced Coffee Consumption Among Individuals With Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1562-1568.	2.4	38
257	Increased Risk of Hepatobiliary Cancers After Hospitalization for Autoimmune Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1038-1045.e7.	2.4	51
258	Role of liver biopsy in autoimmune liver disease. <i>Diagnostic Histopathology</i> , 2014, 20, 109-118.	0.2	12
259	Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2R $\beta$ <sup>-/-</sup> mice. <i>Journal of Autoimmunity</i> , 2014, 51, 99-108.	3.0	62
260	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	0.4	113
261	Pregnancy with Portal Hypertension. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 163-171.	0.4	58
262	Primary biliary cirrhosis in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 427-433.	1.4	31
263	Pruritus in cholestasis: Facts and fiction. <i>Hepatology</i> , 2014, 60, 399-407.	3.6	179
264	Pregnancy in women with primary biliary cirrhosis. <i>Autoimmunity Reviews</i> , 2014, 13, 931-935.	2.5	41
265	Autoimmunity: From black water fever to regulatory function. <i>Journal of Autoimmunity</i> , 2014, 48-49, 1-9.	3.0	11
267	Overlap of IgG4-related Sclerosing Cholangitis and Primary Biliary Cirrhosis. <i>Internal Medicine</i> , 2014, 53, 1429-1433.	0.3	12
268	Interleukin-33 Promotes Disease Progression in Patients with Primary Biliary Cirrhosis. <i>Tohoku Journal of Experimental Medicine</i> , 2014, 234, 255-261.	0.5	17
269	Osteoporosis and FRAX risk in patients with liver cirrhosis. <i>Revista Médica Del Hospital General De México</i> , 2014, 77, 173-178.	0.0	2
270	Genome-Wide Association Studies in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2015, 35, 392-401.	1.8	59



#	ARTICLE	IF	CITATIONS
271	Anti-mitochondrial M2 antibody-positive autoimmune hepatitis. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1419-1422.	0.8	15
272	Drug treatment of pruritus in liver diseases. <i>Clinical Medicine</i> , 2015, 15, 351-357.	0.8	38
273	Itch and liver: management in primary care. <i>British Journal of General Practice</i> , 2015, 65, e418-e420.	0.7	9
274	Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1382-1385.	0.8	19
275	Cancer and scleroderma. <i>Current Opinion in Rheumatology</i> , 2015, 27, 563-570.	2.0	68
277	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Hepatology</i> , 2015, 62, 1620-1622.	3.6	125
278	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
279	A case of symptomatic primary biliary cirrhosis complicated by Behçet's disease which emerged with joint swelling. <i>Acta Hepatologica Japonica</i> , 2015, 56, 575-583.	0.0	0
280	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. <i>Liver International</i> , 2015, 35, 636-641.	1.9	57
281	Predictive Scores in Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 438-447.	1.1	12
282	Chemokine (CXCL13) ligand 13 promotes intrahepatic chemokine (CXCR5) receptor 5+ lymphocyte homing and aberrant B cell immune responses in primary biliary cirrhosis. <i>Hepatology</i> , 2015, 61, 1998-2007.	3.6	45
283	Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 221-230.	1.9	42
284	Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e1243.	0.4	14
285	Autoimmune liver disease and concomitant extrahepatic autoimmune disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1175-1179.	0.8	60
286	A Concise Review of Autoimmune Liver Diseases. , 0, , .		3
287	Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. <i>World Journal of Hepatology</i> , 2015, 7, 926.	0.8	84
288	Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis. <i>The Ewha Medical Journal</i> , 2015, 38, 106.	0.1	0
289	Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0131658.	1.1	24



#	ARTICLE	IF	CITATIONS
290	Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 15-46.	0.3	11
292	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	1.4	22
293	SP140L, an Evolutionarily Recent Member of the SP100 Family, Is an Autoantigen in Primary Biliary Cirrhosis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-17.	0.9	13
294	Serum IgG Subclasses in Autoimmune Diseases. <i>Medicine (United States)</i> , 2015, 94, e387.	0.4	79
295	Liver and the Biliary Tract. , 2015, , 1695-1717.		0
296	Human autoimmune diseases: a comprehensive update. <i>Journal of Internal Medicine</i> , 2015, 278, 369-395.	2.7	681
297	RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial: Figure 1. <i>BMJ Open</i> , 2015, 5, e007985.	0.8	19
299	Rifampin (INN Rifampicin). <i>Journal of Pain and Symptom Management</i> , 2015, 50, 891-895.	0.6	7
300	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	0.7	36
301	Reply. <i>Gastroenterology</i> , 2015, 149, 508-509.	0.6	0
302	Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. <i>Digestive Diseases</i> , 2015, 33, 125-133.	0.8	9
303	Pathogenesis and Management of Pruritus in PBC and PSC. <i>Digestive Diseases</i> , 2015, 33, 164-175.	0.8	61
304	Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. <i>Digestive Diseases</i> , 2015, 33, 118-124.	0.8	4
305	Worldwide Incidence of Autoimmune Liver Disease. <i>Digestive Diseases</i> , 2015, 33, 2-12.	0.8	88
306	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 633-643.	0.9	31
307	The Coexistence of Sjögren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 301-315.	2.9	35
308	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
309	Novel therapeutic targets in primary biliary cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 147-158.	8.2	110

#	ARTICLE	IF	CITATIONS
312	Multiple Genetic Variants Associated with Primary Biliary Cirrhosis in a Han Chinese Population. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 316-321.	2.9	42
313	Increased Numbers of Circulating ICOS+ Follicular Helper T and CD38+ Plasma Cells in Patients with Newly Diagnosed Primary Biliary Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 405-413.	1.1	19
314	Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. <i>Journal of Gastroenterology</i> , 2015, 50, 675-682.	2.3	37
315	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. <i>Digestive and Liver Disease</i> , 2015, 47, 877-883.	0.4	10
316	Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6619-6629.	2.9	7
317	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1435-1444.	1.0	8
318	Overlap syndromes of autoimmune hepatitis: diagnosis and treatment. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2015, 80, 150-159.	0.1	5
319	Glycyrrhizin, silymarin, and ursodeoxycholic acid regulate a common hepatoprotective pathway in HepG2 cells. <i>Phytomedicine</i> , 2015, 22, 768-777.	2.3	40
320	Primary biliary cirrhosis: proposal for a new simple histological scoring system. <i>Liver International</i> , 2015, 35, 652-659.	1.9	22
321	Towards the serological diagnosis of primary biliary cirrhosis. <i>Liver International</i> , 2015, 35, 299-301.	1.9	1
322	Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 857-864.	0.2	115
323	Anti-Î²-tubulin and anti-Î³-tubulin: novel autoantibodies in primary biliary cirrhosis. <i>Liver International</i> , 2015, 35, 642-651.	1.9	66
324	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , 2015, 62, S25-S37.	1.8	406
325	ACG Clinical Guideline: Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 646-659.	0.2	400
326	Transplantation for Primary Biliary Cirrhosis. , 2015, , 159-166.		0
327	A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. <i>Journal of Gastroenterology</i> , 2015, 50, 984-995.	2.3	52
328	Associations Between Magnetic Resonance Imaging Findings and Scores of Liver Function and Histology in Patients with Primary Biliary Cirrhosis. <i>Applied Magnetic Resonance</i> , 2015, 46, 731-739.	0.6	2
329	Women and Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 285-300.	2.9	35

#	ARTICLE	IF	CITATIONS
330	Unmet Challenges in Immune-Mediated Hepatobiliary Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 127-131.	2.9	26
331	Characterization and treatment of persistent hepatocellular secretory failure. <i>Liver International</i> , 2015, 35, 1478-1488.	1.9	24
332	Scandinavian epidemiological research in gastroenterology and hepatology. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 636-648.	0.6	4
333	New simple prognostic score for primary biliary cirrhosis: Albuminâ€bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	1.4	95
334	S100A12 expression in patients with primary biliary cirrhosis. <i>Immunological Investigations</i> , 2015, 44, 13-22.	1.0	5
335	Autoantibody status and histological variables influence biochemical response to treatment and longâ€term outcomes in <sc>Japanese patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2015, 45, 846-855.	1.8	34
336	The Cholangiopathies. <i>Mayo Clinic Proceedings</i> , 2015, 90, 791-800.	1.4	167
337	Synthesis of diastereomerically pure Lys( <i>N</i> - $\mu$ -lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoylâ€containing peptides for diagnosis of primary biliary cirrhosis. <i>Journal of Peptide Science</i> , 2015, 21, 408-414.	0.8	10
338	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. <i>Redox Report</i> , 2015, 20, 33-41.	1.4	34
339	Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2015, 94, e609.	0.4	17
340	Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 132-141.	2.9	50
341	Mycobacteria and autoimmunity. <i>Lupus</i> , 2015, 24, 374-381.	0.8	29
342	Changing Nomenclature for PBC: From â€Cirrhosisâ€ to â€Cholangitisâ€. <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.2	30
343	Changing nomenclature for PBC: From â€cirrhosisâ€ to â€cholangitisâ€. <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.4	15
344	Changing Nomenclature for PBC: From â€Cirrhosisâ€ to â€Cholangitisâ€. <i>Gastroenterology</i> , 2015, 149, 1627-1629.	0.6	96
345	Changing Nomenclature for PBC: From â€Cirrhosisâ€ to â€Cholangitisâ€. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	2.4	16
346	In recurrent primary biliary cirrhosis after liver transplantation, biliary epithelial cells show increased expression of mitochondrial proteins. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 417-425.	1.4	12
347	A decline of LAMP-2 predicts ursodeoxycholic acid response in primary biliary cirrhosis. <i>Scientific Reports</i> , 2015, 5, 9772.	1.6	4

#	ARTICLE	IF	CITATIONS
348	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
349	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	1.8	85
350	Complications of cholestasis. <i>Medicine</i> , 2015, 43, 666-668.	0.2	1
351	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. <i>Journal of Hepatology</i> , 2015, 63, 1449-1458.	1.8	84
352	Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e109.	1.3	23
353	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	6.1	28
354	Diagnóstico y tratamiento de los síndromes de sobreposición de hepatitis autoinmune. <i>Revista De Gastroenterología De México</i> , 2015, 80, 150-159.	0.4	7
355	Primary biliary cirrhosis. <i>Lancet, The</i> , 2015, 386, 1565-1575.	6.3	502
356	Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. <i>Liver International</i> , 2015, 35, 263-274.	1.9	57
357	Diagnosis and Management of Overlap Syndromes. <i>Clinics in Liver Disease</i> , 2015, 19, 81-97.	1.0	30
358	New Therapies for Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 263-272.	2.9	34
359	CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. <i>Hepatology</i> , 2015, 61, 627-638.	3.6	104
360	Lysophosphatidic acid and signaling in sensory neurons. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 61-65.	1.2	19
361	Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. <i>Clinica Chimica Acta</i> , 2015, 438, 135-138.	0.5	31
362	Liver damage in primary biliary cirrhosis and accompanied by primary Sjögren's syndrome: a retrospective pilot study. <i>Central-European Journal of Immunology</i> , 2016, 2, 182-187.	0.4	8
363	Cirrhosis and autoimmune liver disease: Current understanding. <i>World Journal of Hepatology</i> , 2016, 8, 1157.	0.8	47
364	Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 192-205.	0.7	17
365	Recent advances in understanding and managing cholestasis. <i>F1000Research</i> , 2016, 5, 705.	0.8	46

#	ARTICLE	IF	CITATIONS
366	A Patient With Primary Biliary Cirrhosis Accompanied by Wilson's Disease. <i>Hepatitis Monthly</i> , 2016, 16, e29077.	0.1	1
367	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. <i>Gut and Liver</i> , 2016, 10, 177.	1.4	124
368	Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. <i>Hepatic Medicine: Evidence and Research</i> , 2016, Volume 8, 89-95.	0.9	35
369	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases. <i>Diseases (Basel, Switzerland)</i> , 2016, 4, 38.	1.0	4
370	Interleukin-17A-Induced Epithelial-Mesenchymal Transition of Human Intrahepatic Biliary Epithelial Cells: Implications for Primary Biliary Cirrhosis. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 240, 269-275.	0.5	24
371	Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, S3-S15.	0.5	23
372	Vitamin D deficiency in patients with liver cirrhosis. <i>Annals of Gastroenterology</i> , 2016, 29, 297-306.	0.4	67
373	Bile acid derivatives for people with primary biliary cholangitis. <i>The Cochrane Library</i> , 0, , .	1.5	0
374	Recent advances in the diagnosis and treatment of primary biliary cholangitis. <i>World Journal of Hepatology</i> , 2016, 8, 1419.	0.8	24
375	The relationship between liver histology and noninvasive markers in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 773-776.	0.8	25
376	Low incidence of primary biliary cirrhosis (<sc>PBC</sc>) in the first-degree relatives of <sc>PBC</sc> probands after 8 years of follow-up. <i>Liver International</i> , 2016, 36, 1378-1382.	1.9	22
377	The dynamic and clinical significance of autoantibodies and immunoglobulins in liver transplant recipients. <i>Clinical Transplantation</i> , 2016, 30, 241-246.	0.8	3
378	Primary biliary cholangitis associated with warm autoimmune hemolytic anemia. <i>Journal of Digestive Diseases</i> , 2016, 17, 128-131.	0.7	5
379	The UK PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. <i>Hepatology</i> , 2016, 63, 930-950.	3.6	269
380	It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology. <i>Hepatology Research</i> , 2016, 46, 407-415.	1.8	8
381	High-throughput T cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. <i>Hepatology</i> , 2016, 63, 1608-1619.	3.6	104
382	Impact of serum <i>Wisteria floribunda</i> agglutinin positive Mac-2-binding protein and serum interferon- $\beta$ -inducible protein-10 in primary biliary cirrhosis. <i>Hepatology Research</i> , 2016, 46, 575-583.	1.8	40
383	The expression of miR-125b is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen. <i>Journal of Viral Hepatitis</i> , 2016, 23, 330-339.	1.0	35

#	ARTICLE	IF	CITATIONS
384	Bile Acids and the Potential Role in Primary Biliary Cirrhosis. <i>Digestion</i> , 2016, 94, 145-153.	1.2	28
385	Cholestatic Liver Injury: Care of Patients With Primary Biliary Cholangitis or Primary Sclerosing Cholangitis. <i>AACN Advanced Critical Care</i> , 2016, 27, 441-452.	0.6	5
386	Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein. <i>Scientific Reports</i> , 2016, 6, 39838.	1.6	97
387	A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. <i>Medicine (United States)</i> , 2016, 95, e5391.	0.4	27
389	Targets and investigative treatments for primary biliary cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1011-1020.	0.5	0
390	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). <i>Autoimmunity Reviews</i> , 2016, 15, 795-800.	2.5	31
391	The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. <i>Biomedicine and Pharmacotherapy</i> , 2016, 81, 318-328.	2.5	49
393	A case of an elderly patient with primary biliary cirrhosis. <i>European Geriatric Medicine</i> , 2016, 7, 366-368.	1.2	0
394	Novel bile acid therapeutics for the treatment of chronic liver diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 376-391.	1.4	38
395	73-Year-Old Woman With Pruritus, Jaundice, and Altered Mental Status. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1287-1291.	1.4	0
396	Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e3114.	0.4	38
397	Novel Aspects in the Management of Cholestatic Liver Diseases. <i>Digestive Diseases</i> , 2016, 34, 340-346.	0.8	15
398	The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 553-561.	0.7	27
399	Itch Management: Physical Approaches (UV Phototherapy, Acupuncture). <i>Current Problems in Dermatology</i> , 2016, 50, 54-63.	0.8	8
400	MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis. <i>Laboratory Investigation</i> , 2016, 96, 1165-1177.	1.7	28
401	Management of Esophageal Variceal Bleeding. , 2016, , 27-39.		0
402	The interrelationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1039-1050.	1.9	54
403	Molecular diagnostic testing for primary biliary cholangitis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1001-1010.	1.5	30

#	ARTICLE	IF	CITATIONS
404	The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 294-302.	1.9	56
405	Obeticholic acid for the treatment of primary biliary cholangitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1809-1815.	0.9	39
406	Combined ursodeoxycholic acid (<sc>UDCA</sc>) and fenofibrate in primary biliary cholangitis patients with incomplete <sc>UDCA</sc> response may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 283-293.	1.9	109
407	Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 650-651.	1.9	0
408	Elevation of VÎ1 T cells in peripheral blood and livers of patients with primary biliary cholangitis. <i>Clinical and Experimental Immunology</i> , 2016, 186, 347-355.	1.1	5
409	Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. <i>Alcohol</i> , 2016, 54, 61-65.	0.8	5
410	Primary Biliary Cholangitis â€” A New Name and a New Treatment. <i>New England Journal of Medicine</i> , 2016, 375, 685-687.	13.9	10
411	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
412	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1091-1099.	1.4	12
413	Autoimmune liver diseases in the Asiaâ€”Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. <i>Hepatology International</i> , 2016, 10, 909-915.	1.9	41
414	Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3037-3044.	1.1	65
415	Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. <i>Scientific Reports</i> , 2016, 6, 29770.	1.6	27
416	Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 311-318.	0.4	26
417	Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis. <i>SpringerPlus</i> , 2016, 5, 777.	1.2	29
418	The assessment of subjective symptoms and patient-reported outcomes in patients with primary biliary cholangitis using PBC-40. <i>Acta Hepatologica Japonica</i> , 2016, 57, 457-467.	0.0	5
419	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. <i>BMC Gastroenterology</i> , 2016, 16, 71.	0.8	31
420	Acute-on-chronic and Decompensated Chronic Liver Failure. <i>Critical Care Clinics</i> , 2016, 32, 301-309.	1.0	15
422	Toward precision medicine in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2016, 48, 843-850.	0.4	12



#	ARTICLE	IF	CITATIONS
424	Prognostic implications of extra-hepatic clinical manifestations, autoimmunity and microscopic nail capillaroscopy in patients with primary biliary cirrhosis. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 8-15.	0.1	0
425	Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. <i>Gastroenterology Report</i> , 2016, 5, gov064.	0.6	2
426	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
427	Autoimmune Hepatitis Type 2 Associated With Positive Antimitochondrial Antibodies. <i>Clinical Pediatrics</i> , 2016, 55, 479-482.	0.4	5
428	Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 745-752.	0.6	36
429	Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1692-1699.	1.1	49
430	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 13-26.	1.3	51
431	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. <i>Hepatology</i> , 2016, 63, 644-659.	3.6	57
432	Therapeutic advances for primary biliary cholangitis: the old and the new. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 615-621.	0.8	7
433	ACG Clinical Guideline: Liver Disease and Pregnancy. <i>American Journal of Gastroenterology</i> , 2016, 111, 176-194.	0.2	199
434	Emerging drugs for the treatment of Primary Biliary Cholangitis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 39-56.	1.0	16
435	Novel Therapies on Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2016, 20, 113-130.	1.0	8
436	Proposed therapies in primary biliary cholangitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 371-382.	1.4	10
437	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinics in Liver Disease</i> , 2016, 20, 131-142.	1.0	16
438	The management of autoimmunity in patients with cholestatic liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 73-91.	1.4	12
439	The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 50, 114-123.	2.9	53
440	Liver Transplantation for Cholestatic Liver Diseases in Adults. <i>Clinics in Liver Disease</i> , 2016, 20, 191-203.	1.0	39
441	A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. <i>Frontline Gastroenterology</i> , 2016, 7, 158-166.	0.9	26



#	ARTICLE	IF	CITATIONS
442	Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 50, 390-403.	2.9	33
444	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. <i>Cellular and Molecular Immunology</i> , 2017, 14, 276-284.	4.8	51
445	A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. <i>American Journal of Therapeutics</i> , 2017, 24, e167-e176.	0.5	46
446	Update on pharmacotherapies for cholestatic liver disease. <i>Hepatology Communications</i> , 2017, 1, 7-17.	2.0	16
447	Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. <i>Modern Pathology</i> , 2017, 30, 773-783.	2.9	79
448	Diagnostic considerations for cholestatic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1303-1309.	1.4	37
449	Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. <i>Human Molecular Genetics</i> , 2017, 26, ddw406.	1.4	46
450	Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2017, 47, 1252-1259.	1.8	18
451	The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 733-743.	1.9	61
452	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 299-309.	1.0	14
453	Bile acids and cardiovascular function in cirrhosis. <i>Liver International</i> , 2017, 37, 1420-1430.	1.9	44
454	Liver immunology. , 2017, , 173-187.e2.		0
455	Primary biliary cholangitis: new treatments for an old disease. <i>Frontline Gastroenterology</i> , 2017, 8, 29-36.	0.9	8
456	Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation. <i>Journal of Autoimmunity</i> , 2017, 78, 19-28.	3.0	28
457	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. <i>Lancet, The</i> , 2017, 389, 1114-1123.	6.3	157
458	Bile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis. <i>Digestive Diseases</i> , 2017, 35, 210-216.	0.8	26
459	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. <i>American Journal of Medicine</i> , 2017, 130, 744.e1-744.e7.	0.6	28
460	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1363-1372.	1.1	4

#	ARTICLE	IF	CITATIONS
461	miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 66, 1223-1230.	1.8	37
462	Geoeidemiology and changing mortality in primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2017, 52, 655-662.	2.3	16
463	A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. <i>Nature Communications</i> , 2017, 8, 14828.	5.8	102
464	Apamin suppresses biliary fibrosis and activation of hepatic stellate cells. <i>International Journal of Molecular Medicine</i> , 2017, 39, 1188-1194.	1.8	17
465	Obeticholic Acid. <i>Journal of Pharmacy Technology</i> , 2017, 33, 66-71.	0.5	6
466	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 145-172.	1.8	889
467	Diagnostic autoantibodies for autoimmune liver diseases. <i>Clinical and Translational Immunology</i> , 2017, 6, e139.	1.7	22
468	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017, 49, 841-846.	0.4	23
470	The emerging role of mast cells in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G89-G101.	1.6	34
471	What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?. <i>Digestive Diseases</i> , 2017, 35, 359-366.	0.8	8
472	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. <i>Gastroenterology</i> , 2017, 152, 1536-1543.	0.6	121
473	Pathological Features of Biliary Disease in Children and Adults. , 2017, , 43-61.		0
474	Primary Biliary Cholangitis: Its Science and Practice. , 2017, , 129-182.		0
475	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 345-364.	1.0	22
476	Treatment of primary biliary cholangitis ursodeoxycholic acid nonresponders: A systematic review. <i>Liver International</i> , 2017, 37, 1877-1886.	1.9	27
477	Coexistent Primary Biliary Cholangitis with CREST Syndrome (Reynolds Syndrome). <i>American Journal of Medicine</i> , 2017, 130, e501-e502.	0.6	5
478	Endoscopy in Pregnant Women With Liver Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 329-330.	0.6	1
479	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017, 37, 159-174.	1.8	26

#	ARTICLE	IF	CITATIONS
480	Finding the cure for primary biliary cholangitis – Still waiting. <i>Liver International</i> , 2017, 37, 500-502.	1.9	21
481	The Clinical Burden of Biliary Disease: A Global Perspective. , 2017, , 1-15.		1
482	Pharmacological interventions for primary biliary cholangitis. <i>The Cochrane Library</i> , 2017, 2017, CD011648.	1.5	21
483	Old and new treatments for primary biliary cholangitis. <i>Liver International</i> , 2017, 37, 490-499.	1.9	37
484	Human Î²-Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e80.	1.3	3
485	Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis. <i>Toxicology</i> , 2017, 377, 73-80.	2.0	8
486	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. <i>American Journal of Gastroenterology</i> , 2017, 112, 18-35.	0.2	672
487	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 394-412.	2.9	27
488	Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population. <i>Clinical Medicine and Research</i> , 2017, 15, 13-18.	0.4	12
489	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000158.	1.1	3
490	Novel strategies and therapeutic options for the management of primary biliary cholangitis. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 791-803.	1.4	12
491	Investigational drugs in phase II clinical trials for primary biliary cholangitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1115-1121.	1.9	6
492	A brief review on prognostic models of primary biliary cholangitis. <i>Hepatology International</i> , 2017, 11, 412-418.	1.9	15
493	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e116.	1.3	48
494	Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients. <i>Journal of Human Genetics</i> , 2017, 62, 963-967.	1.1	20
495	The Challenges of Nutritional Assessment in Cirrhosis. <i>Current Nutrition Reports</i> , 2017, 6, 274-280.	2.1	13
496	Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00329.	1.1	36
497	Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 885-896.	2.5	158

#	ARTICLE	IF	CITATIONS
498	Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba. <i>Current Therapeutic Research</i> , 2017, 85, 8-14.	0.5	2
499	An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2017, 21, 709-723.	1.0	10
500	Toward solving the etiological mystery of primary biliary cholangitis. <i>Hepatology Communications</i> , 2017, 1, 275-287.	2.0	28
501	Circulating follicular helper T cells presented distinctively different responses toward bacterial antigens in primary biliary cholangitis. <i>International Immunopharmacology</i> , 2017, 51, 76-81.	1.7	8
503	Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies. <i>European Neurology</i> , 2017, 78, 290-295.	0.6	22
504	Primary biliary cholangitis: symptoms, diagnosis and treatment. <i>Gastrointestinal Nursing</i> , 2017, 15, S12-S17.	0.0	1
505	Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. <i>Scientific Reports</i> , 2017, 7, 15307.	1.6	72
506	A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization. <i>Scientific Reports</i> , 2017, 7, 15246.	1.6	3
507	Gallbladder and bile duct disease in Cystic Fibrosis. <i>Journal of Cystic Fibrosis</i> , 2017, 16, S62-S69.	0.3	42
508	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e100.	1.3	23
509	Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. <i>Current Hepatology Reports</i> , 2017, 16, 119-123.	0.4	12
510	Obeticholic acid in primary biliary cholangitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 3-5.	0.7	7
511	Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages. <i>Journal of Clinical Lipidology</i> , 2017, 11, 110-118.	0.6	20
512	Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2017, 464, 113-117.	0.5	22
513	Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. <i>Journal of Rheumatology</i> , 2017, 44, 33-39.	1.0	23
514	Distinctive HLA association with primary biliary cholangitis on the Island of Sardinia. <i>United European Gastroenterology Journal</i> , 2017, 5, 527-531.	1.6	11
515	Evidence for the association between IgG anti-mitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 659-666.	1.4	15
516	Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?. <i>Immunologic Research</i> , 2017, 65, 299-306.	1.3	4

#	ARTICLE	IF	CITATIONS
517	Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. <i>Modern Rheumatology</i> , 2017, 27, 664-668.	0.9	18
518	Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: Could it be primary biliary cholangitis?. <i>Hepatology Research</i> , 2017, 47, 742-746.	1.8	10
519	Extensive testing or focused testing of patients with elevated liver enzymes. <i>Journal of Hepatology</i> , 2017, 66, 313-319.	1.8	28
520	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 152-163.	3.6	93
521	Association between serum soluble <scp>CD</scp>14 and <scp>IL</scp>8 levels and clinical outcome in primary biliary cholangitis. <i>Liver International</i> , 2017, 37, 897-905.	1.9	22
523	Imaging of autoimmune biliary disease. <i>Abdominal Radiology</i> , 2017, 42, 3-18.	1.0	10
524	Stress-induced cellular responses and cell death mechanisms during inflammatory cholangiopathies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 129-138.	0.7	10
526	Chromosome 17q21 Genes ORMDL3 and GSDMB in Asthma and Immune Diseases. <i>Advances in Immunology</i> , 2017, 135, 1-52.	1.1	91
527	Pathological patterns of biliary disease. <i>Clinical Liver Disease</i> , 2017, 10, 107-110.	1.0	12
528	Anti-mitochondrial autoantibodiesâ€”milestone or byway to primary biliary cholangitis?. <i>Annals of Translational Medicine</i> , 2017, 5, 50-50.	0.7	4
529	Serological tests for primary biliary cholangitis. <i>The Cochrane Library</i> , 2017, , .	1.5	0
530	Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability. <i>Annals of Hepatology</i> , 2017, 16, 430-435.	0.6	9
531	Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000177.	1.1	1
532	Ursodeoxycholic Acid for the Treatment of Liver Diseases. , 2017, , 767-779.		2
534	Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. <i>Archives of Medical Science</i> , 2018, 14, 930-940.	0.4	3
535	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 16498-16506.	0.8	35
536	Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	17
537	Risk of liver disease in methotrexate treated patients. <i>World Journal of Hepatology</i> , 2017, 9, 1092.	0.8	111

#	ARTICLE	IF	CITATIONS
538	Reversal of liver cirrhosis: current evidence and expectations. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 213-228.	0.7	100
539	Elevated Liver Enzymes in Asymptomatic Patients – What Should I Do?. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 1-10.	0.7	67
540	Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. <i>PLoS ONE</i> , 2017, 12, e0178580.	1.1	36
541	MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. <i>PLoS ONE</i> , 2017, 12, e0184292.	1.1	16
542	A case of asymptomatic non-cirrhotic primary biliary cholangitis showing splenorenal shunt with neither anti-mitochondrial antibody nor M2 antibody. <i>Acta Hepatologica Japonica</i> , 2017, 58, 38-45.	0.0	1
543	Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis. <i>Scientific Reports</i> , 2017, 7, 796.	1.6	12
544	[RETRACTED ARTICLE] Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e5234.	0.7	1
545	Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 214.	1.8	24
546	The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. <i>Molecular Medicine Reports</i> , 2017, 17, 3837-3844.	1.1	4
547	Extrahepatic Manifestations of Primary Biliary Cholangitis. <i>Gut and Liver</i> , 2017, 11, 771-780.	1.4	61
548	Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis. <i>International Immunopharmacology</i> , 2018, 56, 285-290.	1.7	5
549	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1213-1219.	1.9	23
550	Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome. <i>Medicine (United States)</i> , 2018, 97, e0004.	0.4	8
551	Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. <i>United European Gastroenterology Journal</i> , 2018, 6, 247-254.	1.6	10
552	Metabolomics Profiles of Hepatocellular Carcinoma in a Korean Prospective Cohort: The Korean Cancer Prevention Study-II. <i>Cancer Prevention Research</i> , 2018, 11, 303-312.	0.7	45
554	Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures. <i>Current Hepatology Reports</i> , 2018, 17, 143-151.	0.4	1
555	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. <i>Journal of Gastroenterology</i> , 2018, 53, 1151-1158.	2.3	29
556	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	1.9	22

#	ARTICLE	IF	CITATIONS
557	Clinical connection between rheumatoid arthritis and liver damage. <i>Rheumatology International</i> , 2018, 38, 715-724.	1.5	40
558	Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. <i>Medical Molecular Morphology</i> , 2018, 51, 176-185.	0.4	5
559	Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. <i>Hepatology Research</i> , 2018, 48, 727-734.	1.8	4
560	Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1286-1294.	1.4	22
561	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 282-294.	2.9	36
562	Geoeidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 295-306.	2.9	12
563	Definitions, Epidemiology and Prognostication of Liver Disease. , 2018, , 75-82.		2
564	Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation. <i>Digestive Diseases and Sciences</i> , 2018, 63, 529-532.	1.1	5
565	Itching to Know: Role of Fibrates in PBC. <i>American Journal of Gastroenterology</i> , 2018, 113, 56-57.	0.2	3
566	Evaluation of abnormal liver tests in the adult asymptomatic patient. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 272-279.	1.0	9
567	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. <i>Gut</i> , 2018, 67, 1568-1594.	6.1	217
568	Colangitis biliar primaria. <i>Medicina Clínica</i> , 2018, 151, 242-249.	0.3	14
569	An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. <i>Laboratory Investigation</i> , 2018, 98, 745-754.	1.7	29
570	Monoclonal gammopathy in rheumatic diseases. <i>Clinical Rheumatology</i> , 2018, 37, 1751-1762.	1.0	22
571	Red blood cell distribution width to platelet ratio levels in assessment of histologic severity in patients with primary biliary cholangitis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 258-263.	0.6	9
572	Autoimmune manifestations of infections. <i>Current Opinion in Rheumatology</i> , 2018, 30, 373-379.	2.0	24
573	Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis. <i>Medicine (United States)</i> , 2018, 97, e9843.	0.4	5
574	Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. <i>Gut</i> , 2018, 67, 534-541.	6.1	330



#	ARTICLE	IF	CITATIONS
575	Possible involvement of chemokine CCR7 programmed cell death-1 <sup>+</sup> follicular helper T cell subset in the pathogenesis of autoimmune hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 298-306.	1.4	18
576	Primary biliary cholangitis: Old and novel therapy. <i>European Journal of Internal Medicine</i> , 2018, 47, 1-5.	1.0	54
577	Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 156-161.	0.4	23
578	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1333-1341.e6.	2.4	42
579	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
580	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 849-857.	1.6	16
581	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , 2018, 48, E252-E262.	1.8	37
582	Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis. <i>Liver International</i> , 2018, 38, 542-552.	1.9	8
583	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. <i>Liver International</i> , 2018, 38, 399-411.	1.9	30
584	Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. <i>Clinical Journal of Gastroenterology</i> , 2018, 11, 11-18.	0.4	36
585	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64
586	Scratching the surface of cholestatic itch treatments. <i>Hepatology</i> , 2018, 67, 2045-2048.	3.6	4
587	Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. <i>Liver International</i> , 2018, 38, 1110-1116.	1.9	8
588	Gastrointestinal and Hepatic Disease in Sjogren Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 143-151.	0.8	29
589	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
591	Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis. <i>Hepatology</i> , 2018, 68, 166-171.	3.6	18
592	MicroRevolution in understanding primary biliary cholangitis pathophysiology. <i>Hepatology</i> , 2018, 67, 1213-1215.	3.6	1
593	An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis. <i>Annals of Hepatology</i> , 2018, 17, 920-932.	0.6	21



#	ARTICLE	IF	CITATIONS
594	Increased red cell width distribution to lymphocyte ratio is a predictor of histologic severity in primary biliary cholangitis. <i>Medicine (United States)</i> , 2018, 97, e13431.	0.4	13
595	Primary biliary cholangitis: an update on treatment. <i>Gastrointestinal Nursing</i> , 2018, 16, S10-S14.	0.0	0
596	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.1	3
597	Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. <i>Gastroenterology Research</i> , 2018, 11, 83-94.	0.4	50
598	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. <i>CMAJ Open</i> , 2018, 6, E664-E670.	1.1	12
599	Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. <i>Journal of Liver</i> , 2018, 07, .	0.3	6
600	Managing PBC: Expanding the Provider Comfort Zone. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2487-2488.	1.1	0
601	Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 231, 180-187.	0.5	135
602	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. <i>Journal of Hepatology</i> , 2018, 69, 1371-1383.	1.8	35
603	NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. <i>Hepatology Communications</i> , 2018, 2, 1037-1050.	2.0	96
604	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. <i>PLoS ONE</i> , 2018, 13, e0203084.	1.1	43
605	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. <i>Scientific Reports</i> , 2018, 8, 12542.	1.6	17
606	Cholestatic liver diseases: new targets, new therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878740.	1.4	61
607	Regulation of bile secretion by calcium signaling in health and disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1761-1770.	1.9	22
608	Understanding and Treating Pruritus in Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 517-532.	1.0	21
609	Current Treatment Options for Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 481-500.	1.0	9
610	Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2018, 8, 8159.	1.6	32
611	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018, 5, 287-296.	1.6	7

#	ARTICLE	IF	CITATIONS
612	Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. <i>PLoS ONE</i> , 2018, 13, e0198757.	1.1	69
613	Evolution of our understanding of PBC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 3-9.	1.0	29
614	The Genetics and Epigenetics of Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 443-455.	1.0	27
615	Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era. <i>Clinics in Liver Disease</i> , 2018, 22, 563-578.	1.0	32
616	Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 603-611.	1.0	17
617	Distribution of Connective Tissue in the Male and Female Porcine Liver: Histological Mapping and Recommendations for Sampling. <i>Journal of Comparative Pathology</i> , 2018, 162, 1-13.	0.1	13
618	Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e169.	1.3	13
619	Association between STAT4 polymorphisms and risk of primary biliary cholangitis: a meta-analysis. <i>Genes and Genomics</i> , 2018, 40, 1101-1109.	0.5	1
620	Deviations in Peripheral Blood Cell Populations are Associated with the Stage of Primary Biliary Cholangitis and Presence of Itching. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 443-452.	1.0	13
621	Liver Illness and Psoriatic Patients. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	52
622	Symptoms of PBC – Pathophysiology and management. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 41-47.	1.0	22
623	Biomarkers for primary biliary cholangitis: current perspectives. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 43-53.	0.9	16
624	A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. <i>BMC Gastroenterology</i> , 2018, 18, 97.	0.8	5
625	Bile Duct Diseases. , 2018, , 515-593.		12
626	Antimitochondrial Antibody–Negative Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 589-601.	1.0	11
627	Current Status of Liver Transplantation for Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 613-624.	1.0	20
628	Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. <i>Autoimmunity Reviews</i> , 2018, 17, 866-872.	2.5	22
629	Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2547-2554.	1.1	6

#	ARTICLE	IF	CITATIONS
630	External validation of the United Kingdomâ€”primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 676-682.	2.0	6
631	Primary biliary cholangitis. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 242-249.	0.1	4
632	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDPâ€”305, a novel farnesoid X receptor agonist. <i>Hepatology Communications</i> , 2018, 2, 821-835.	2.0	46
633	Work in Progress. <i>Clinics in Liver Disease</i> , 2018, 22, 501-515.	1.0	1
634	Chronic Complications of Cholestasis. <i>Clinics in Liver Disease</i> , 2018, 22, 533-544.	1.0	21
635	Primary Biliary Cholangitis. , 2018, , 409-421.		0
636	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2018, 378, 2171-2181.	13.9	383
637	Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1352-1360.	0.8	6
639	A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity. <i>Internal Medicine</i> , 2018, 57, 3093-3097.	0.3	0
640	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). <i>PLoS ONE</i> , 2018, 13, e0193960.	1.1	22
641	Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 71-83.	1.0	10
642	Improving prognosis in primary biliary cholangitis â€” Therapeutic options and strategy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 85-94.	1.0	10
643	Risk stratification and prognostic modelling in primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 95-106.	1.0	10
644	Clinical application of the GLOBE and United Kingdomâ€”primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. <i>Hepatology Communications</i> , 2018, 2, 683-692.	2.0	19
645	Asociaciones autoinmunes en una cohorte mexicana con colangitis biliar primaria. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2019, 84, 130-135.	0.4	6
646	Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2019, 70, 1646-1657.	3.6	48
647	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. <i>Hepatology</i> , 2019, 69, 237-244.	3.6	18
648	High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13691.	1.6	14

#	ARTICLE	IF	CITATIONS
649	A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2019, 3, 1250-1257.	2.0	11
650	Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22965.	0.9	27
651	Endocrine Diseases and the Liver. <i>Clinics in Liver Disease</i> , 2019, 23, 233-246.	1.0	20
652	Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-6.	0.8	9
653	Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5055.	1.8	140
654	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1391-1396.	0.6	8
655	Cholestatic pruritus: Emerging mechanisms and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1371-1378.	0.6	23
656	Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?. <i>Journal of Clinical Pathology</i> , 2019, 72, 669-676.	1.0	9
657	Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. <i>Hepatology International</i> , 2019, 13, 788-799.	1.9	44
658	Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. <i>Epigenomes</i> , 2019, 3, 15.	0.8	7
659	CD4 <sup>+</sup> T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T cell receptor repertoires. <i>Hepatology Research</i> , 2019, 49, 653-662.	1.8	4
660	Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 609-616.	0.6	20
661	Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor $\alpha/\gamma$ Agonist for the Treatment of Primary Biliary Cirrhosis. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1068-1073.	1.3	5
662	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. <i>Liver Research</i> , 2019, 3, 118-127.	0.5	5
663	Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. <i>Canadian Liver Journal</i> , 2019, 2, 31-44.	0.3	11
664	Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database. <i>Transplantation</i> , 2019, 103, 1191-1198.	0.5	3
665	Interleukin-33/ST2-Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis. <i>Hepatology Communications</i> , 2019, 3, 670-684.	2.0	11
666	An ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of obeticholic acid in rat plasma and its application in preclinical pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1121, 82-88.	1.2	4

#	ARTICLE	IF	CITATIONS
667	CTHRC1 expression in primary biliary cholangitis. <i>Journal of Digestive Diseases</i> , 2019, 20, 371-376.	0.7	7
668	Alteration of liver-infiltrated and peripheral blood double-negative T cells in primary biliary cholangitis. <i>Liver International</i> , 2019, 39, 1755-1767.	1.9	9
669	Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. <i>Frontiers in Immunology</i> , 2019, 10, 1026.	2.2	31
670	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1379-1387.e3.	2.4	43
671	Proteomics in Primary Biliary Cholangitis. <i>Methods in Molecular Biology</i> , 2019, 1981, 163-173.	0.4	1
672	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 445-453.	3.7	116
673	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
674	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000256.	1.1	11
675	Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 294-307.	3.6	30
676	Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. <i>Scientific Reports</i> , 2019, 9, 4530.	1.6	43
677	Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 377-383.	0.1	0
678	Current and promising therapy for primary biliary cholangitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1161-1167.	0.9	10
679	Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 2035-2046.	3.6	83
680	65-Year-Old Woman With Abdominal Pain and Jaundice. <i>Mayo Clinic Proceedings</i> , 2019, 94, e51-e55.	1.4	0
681	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2019, 3, 365-381.	2.0	58
682	Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. <i>Japanese Journal of Radiology</i> , 2019, 37, 412-419.	1.0	5
683	Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. <i>Autoimmunity Highlights</i> , 2019, 10, 10.	3.9	6
684	Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China. <i>Scientific Reports</i> , 2019, 9, 19680.	1.6	2

#	ARTICLE	IF	CITATIONS
685	Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 1593-1605.	0.2	28
686	Primary biliary cholangitis: an update on treatment. Gastrointestinal Nursing, 2019, 17, S14-S16.	0.0	0
687	Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. International Journal of Cancer, 2019, 144, 707-717.	2.3	20
688	Association of CCL11, CCL24 and CCL26 with primary biliary cholangitis. International Immunopharmacology, 2019, 67, 372-377.	1.7	6
689	Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Alimentary Pharmacology and Therapeutics, 2019, 49, 285-295.	1.9	37
690	Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies. Life Sciences, 2019, 218, 324-339.	2.0	14
691	Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort. Neuromuscular Disorders, 2019, 29, 5-13.	0.3	23
692	Diagnosis and Management of Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 48-63.	0.2	100
693	Changes in serum levels of leucine-rich Î±2-glycoprotein predict prognosis in primary biliary cholangitis. Hepatology Research, 2019, 49, 385-393.	1.8	9
694	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterology, 2019, 10, 401-408.	0.9	14
695	Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Revista De Gastroenterología De México (English Edition), 2019, 84, 130-135.	0.1	2
696	Análisis de los Índices predictores de respuesta al tratamiento con Ácido ursodeoxicílico en pacientes con colangitis biliar primaria. Medicina Clínica, 2019, 152, 377-383.	0.3	3
697	Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1236-1241.	1.4	15
698	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases. , 2019, , 251-305.		0
699	Primary biliary cholangitis in patients with systemic sclerosis: Unmasking the true face of Reynold's syndrome. Egyptian Rheumatologist, 2020, 42, 31-34.	0.5	2
700	Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. Clinical Reviews in Allergy and Immunology, 2020, 58, 25-38.	2.9	86
701	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Journal of Clinical Densitometry, 2020, 23, 223-236.	0.5	8
702	Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Digestive Diseases and Sciences, 2020, 65, 416-422.	1.1	6

#	ARTICLE	IF	CITATIONS
703	Rosiglitazone alleviates intrahepatic cholestasis induced by Î±-naphthylisothiocyanate in mice: The role of circulating 15â€œdeoxyâ€œ” <sup>12,14</sup>â€œPGJ<sub>2</sub> and Nogo. <i>British Journal of Pharmacology</i> , 2020, 177, 1041-1060.	2.7	16
704	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 673-679.	1.4	10
705	Thigh muscle MRI findings in myopathy associated with antiâ€œmitochondrial antibody. <i>Muscle and Nerve</i> , 2020, 61, 81-87.	1.0	13
706	Treatment of SjÃ¶rgren's syndrome internal organ manifestations and constitutional symptoms. , 2020, , 211-234.		0
707	Clinical utility of FibroScan as a nonâ€œinvasive diagnostic test for primary biliary cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1208-1214.	1.4	17
708	Evaluation of the United Kingdomâ€œprimary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. <i>JGH Open</i> , 2020, 4, 132-139.	0.7	3
709	Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 844-850.	0.8	5
710	Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation. <i>Nutrition in Clinical Practice</i> , 2020, 35, 50-62.	1.1	43
711	Increased p16INK4a-expressing senescent bile ductular cells are associated with inadequate response to ursodeoxycholic acid in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2020, 107, 102377.	3.0	16
712	Chronic Liver Disease in the Obstetric Patient. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 193-210.	0.6	1
713	Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2020, 39, 795-803.	1.0	7
714	Consensus guidelines: best practices for detection, assessment and management of suspected acute drugâ€œinduced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 90-109.	1.9	21
715	Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165958.	1.8	9
716	An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 985-998.	1.4	3
717	Laboratory diagnosis of liver disease. , 2020, , 545-559.		0
718	Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine. <i>Medicine (United States)</i> , 2020, 99, e23107.	0.4	0
719	Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features. <i>Digestive Diseases</i> , 2021, 39, 366-374.	0.8	7
720	Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	2



#	ARTICLE	IF	CITATIONS
721	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2439-2451.	1.1	23
722	Characteristics of serum chemokine profile in primary biliary cholangitis. <i>Cytokine</i> , 2020, 136, 155291.	1.4	5
723	Changed Profile of Serum Transferrin Isoforms in Primary Biliary Cholangitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2894.	1.0	3
724	Do hepatic artery infusion pumps cause recurrent pleural effusions?. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjaa137.	0.2	1
725	Association between serum ficolin-1 level and disease progression in primary biliary cholangitis. <i>PLoS ONE</i> , 2020, 15, e0238300.	1.1	3
726	Replication study and meta-analysis indicate a suggestive association of RUNX3 locus with primary biliary cholangitis. <i>Immunogenetics</i> , 2020, 72, 467-474.	1.2	0
727	Profiling of the pattern of the human TRB/IGH CDR3 repertoire in primary biliary cholangitis patients. <i>International Immunopharmacology</i> , 2020, 83, 106393.	1.7	2
728	PSC and Overlap Syndromes. <i>Current Hepatology Reports</i> , 2020, 19, 106-118.	0.4	2
729	Role of cell autophagy in the generation of IgM and hepatic fibrosis in primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2020, 39, 3499-3506.	1.0	6
730	Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target. <i>Hepatology</i> , 2020, 72, 1838-1850.	3.6	13
731	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 20.	1.0	14
732	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1121-1129.	1.9	15
733	Therapeutic Effects of Apamin as a Bee Venom Component for Non-Neoplastic Disease. <i>Toxins</i> , 2020, 12, 195.	1.5	41
734	Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids. <i>PLoS ONE</i> , 2020, 15, e0229745.	1.1	12
735	Cancer and Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 551-564.	0.8	14
736	Implication of Increased Serum IL-31 for Primary Biliary Cholangitis. <i>Immunological Investigations</i> , 2021, 50, 662-670.	1.0	2
737	Primary biliary cholangitis presenting as acute ischemic stroke: A rare association. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 274-277.	0.2	0
738	Nutritional Management of Cholestasis. <i>Clinical Liver Disease</i> , 2020, 15, 9-12.	1.0	6



#	ARTICLE	IF	CITATIONS
739	Recurrent Disease After Liver Transplantation. <i>Current Hepatology Reports</i> , 2020, 19, 54-62.	0.4	3
740	Aging-Related Molecular Pathways in Chronic Cholestatic Conditions. <i>Frontiers in Medicine</i> , 2019, 6, 332.	1.2	9
741	Emerging therapies for PBC. <i>Journal of Gastroenterology</i> , 2020, 55, 261-272.	2.3	15
742	&lt;p&gt;Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 17-24.	1.0	12
743	Tight Junction Proteins and the Biology of Hepatobiliary Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 825.	1.8	36
744	The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	4
745	Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 874-884.	0.7	5
746	Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 573-579.e1.	2.4	45
747	How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis?. <i>Digestion</i> , 2021, 102, 428-436.	1.2	1
748	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2021, 40, 1819-1826.	1.0	5
749	Investigational drugs in early phase development for primary biliary cholangitis. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 131-141.	1.9	7
750	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 31-38.	1.8	5
751	Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis. <i>Pathology Research and Practice</i> , 2021, 217, 153291.	1.0	10
752	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. <i>JHEP Reports</i> , 2021, 3, 100202.	2.6	22
753	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 321-329.	1.8	55
754	Cholestatic liver disease: Practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 1.	0.5	3
755	Current understanding of primary biliary cholangitis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 1-21.	4.5	63
756	Transplant and Autoimmune Diseases. , 2021, , 281-293.		0

#	ARTICLE	IF	CITATIONS
757	Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. <i>Annals of Gastroenterology</i> , 2021, 34, 229-234.	0.4	2
758	Fibrosis and hepatic regeneration mechanism. <i>Translational Gastroenterology and Hepatology</i> , 2022, 7, 9-9.	1.5	8
759	Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. <i>World Journal of Gastroenterology</i> , 2021, 27, 80-91.	1.4	5
760	Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	3
761	The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal surveyâ€‘based study. <i>Clinical Rheumatology</i> , 2021, 40, 3311-3317.	1.0	1
762	Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-10.	0.8	8
763	The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	6
764	Real-World Clinical Management of Patients with Primary Biliary Cholangitisâ€‘A Retrospective Multicenter Study from Germany. <i>Journal of Clinical Medicine</i> , 2021, 10, 1061.	1.0	11
765	Investigation of immune complexes formed by mitochondrial antigens containing a new lipoylated site in sera of primary biliary cholangitis patients. <i>Clinical and Experimental Immunology</i> , 2021, 204, 335-343.	1.1	2
766	Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	1
767	Expanded circulating peripheral helper T cells in primary biliary cholangitis. <i>Molecular Immunology</i> , 2021, 131, 44-50.	1.0	6
768	Pruritus in autoimmune connective tissue diseases. <i>Annals of Translational Medicine</i> , 2021, 9, 441-441.	0.7	5
769	Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. <i>Hepatology International</i> , 2021, 15, 437-443.	1.9	3
770	Primary biliary cholangitis. <i>Vestnik Transplantologii I Iskusstvennykh Organov</i> , 2021, 23, 162-170.	0.1	0
771	The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. <i>Hepatology International</i> , 2021, 15, 223-257.	1.9	37
772	Early arthritis and digestive diseases. A rheumatologistâ€™s view. <i>Ekspierimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 186-193.	0.1	0
773	Male Sex Is Associated With Higher Rates of Liverâ€‘Related Mortality in Primary Biliary Cholangitis and Cirrhosis. <i>Hepatology</i> , 2021, 74, 879-891.	3.6	36
774	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.2	14

#	ARTICLE	IF	CITATIONS
775	Fibrotic Events in the Progression of Cholestatic Liver Disease. <i>Cells</i> , 2021, 10, 1107.	1.8	24
776	Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
777	Autoimmune liver damage in patients with primary Sjogren's syndrome associated with antientromeric antibodies. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 27-34.	0.1	0
778	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	1.8	77
779	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100276.	2.6	5
780	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
781	Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. <i>Drugs</i> , 2021, 81, 1181-1192.	4.9	37
782	Dynamin-related protein 1 deficiency accelerates lipopolysaccharide-induced acute liver injury and inflammation in mice. <i>Communications Biology</i> , 2021, 4, 894.	2.0	9
783	5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. <i>International Immunopharmacology</i> , 2021, 96, 107820.	1.7	8
785	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101770.	0.7	4
786	Primary biliary cirrhosis in early childhood – A rare case report. <i>International Journal of Surgery Case Reports</i> , 2021, 85, 106215.	0.2	1
787	Downregulation of Programmed Death-1 Pathway Promoting CD8+ T Cell Cytotoxicity in Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2981-2993.	1.1	3
788	Liver Zonation – Revisiting Old Questions With New Technologies. <i>Frontiers in Physiology</i> , 2021, 12, 732929.	1.3	75
789	Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. <i>Clinical Immunology</i> , 2021, 230, 108825.	1.4	2
790	Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1202-1212.	1.9	15
791	The Role of B Cells in Adult and Paediatric Liver Injury. <i>Frontiers in Immunology</i> , 2021, 12, 729143.	2.2	17
792	Ursodeoxycholic Acid at 18 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	4
793	The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease. <i>PLoS ONE</i> , 2021, 16, e0244950.	1.1	5

#	ARTICLE	IF	CITATIONS
794	Baricitinib and primary biliary cholangitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100107.	2.0	13
796	Biliary and Vascular Changes. , 2016, , 37-69.		1
797	Primary Biliary Cholangitis. , 2019, , 221-235.		1
798	Genetic Factors in the Pathogenesis of Primary Biliary Cirrhosis. , 2014, , 157-169.		1
799	Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1343-1348.	1.1	3
801	Liver Disease. , 2012, , 1637-1693.		4
802	Proteinase-activated Receptor 1 Contributed to Up-regulation of Enkephalin in Keratinocytes of Patients with Obstructive Jaundice. <i>Anesthesiology</i> , 2014, 121, 127-139.	1.3	16
803	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1926-1933.	1.9	14
804	Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220824.	0.2	3
805	Scalar-on-function regression for predicting distal outcomes from intensively gathered longitudinal data: Interpretability for applied scientists. <i>Statistics Surveys</i> , 2019, 13, 150-180.	7.3	7
806	Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases. <i>Wellcome Open Research</i> , 2017, 2, 75.	0.9	11
807	Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e101916.	1.1	40
808	The Value of MRI in the Diagnosis of Primary Biliary Cirrhosis and Assessment of Liver Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0120110.	1.1	19
809	Low Serum Hepcidin in Patients with Autoimmune Liver Diseases. <i>PLoS ONE</i> , 2015, 10, e0135486.	1.1	25
810	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0159612.	1.1	23
811	Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study. <i>PLoS ONE</i> , 2018, 13, e0194397.	1.1	11
812	Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 266-84.	0.7	20
813	Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-8.	0.7	11

#	ARTICLE	IF	CITATIONS
814	Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. <i>Journal of Clinical and Translational Hepatology</i> , 2020, X, 1-12.	0.7	28
815	Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1499-1507.	1.4	15
816	Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 557-563.	0.1	23
817	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. <i>Oncotarget</i> , 2015, 6, 28011-28025.	0.8	36
818	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. <i>Oncotarget</i> , 2015, 6, 24533-24549.	0.8	10
819	Management of primary biliary cholangitis prior to obeticholic acid availability. <i>Minerva Medica</i> , 2018, 109, 410-417.	0.3	7
820	Analysis of disease-pathways by susceptibility genes in primary biliary cirrhosis. <i>Inflammation and Regeneration</i> , 2014, 34, 078-086.	1.5	2
821	Indirect immunofluorescence and ELISA for testing of antimitochondrial antibodies -Which is better?-. <i>Acta Hepatologica Japonica</i> , 2010, 51, 531-533.	0.0	2
822	Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 422 T</i>	0.9	8
824	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. <i>World Journal of Gastroenterology</i> , 2012, 18, 4855.	1.4	11
825	Liver diseases in pregnancy: Diseases not unique to pregnancy. <i>World Journal of Gastroenterology</i> , 2013, 19, 7630.	1.4	17
826	Study of liver cirrhosis over ten consecutive years in Southern China. <i>World Journal of Gastroenterology</i> , 2014, 20, 13546.	1.4	47
827	Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations. <i>World Journal of Gastroenterology</i> , 2015, 21, 283.	1.4	18
828	Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 2236-2241.	1.4	6
829	Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 7579.	1.4	12
830	Recent advances in the management of pruritus in chronic liver diseases. <i>World Journal of Gastroenterology</i> , 2017, 23, 3418.	1.4	34
831	Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. <i>World Journal of Gastroenterology</i> , 2017, 23, 4839.	1.4	22
832	Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7191-7197.	1.4	6

#	ARTICLE	IF	CITATIONS
833	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7863-7874.	1.4	7
834	Osteoporosis in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3513-3520.	1.4	29
835	Management of Primary Biliary Cirrhosis. <i>Korean Journal of Medicine</i> , 2012, 82, 32.	0.1	12
836	Autoimmune liver disease and the enteric microbiome. <i>AIMS Microbiology</i> , 2018, 4, 334-346.	1.0	3
837	Recent advances in the development of farnesoid X receptor agonists. <i>Annals of Translational Medicine</i> , 2015, 3, 5.	0.7	115
838	Overlapping of Primary Biliary Cirrhosis and Small Duct Primary Sclerosing Cholangitis: First Case Report. <i>Journal of Clinical Medicine Research</i> , 2012, 4, 429-33.	0.6	20
839	Cutoff values of acoustic radiation force impulse two-location measurements in different etiologies of liver fibrosis. <i>Journal of Medical Ultrasound</i> , 2019, 27, 130.	0.2	4
840	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. <i>World Journal of Hepatology</i> , 2013, 5, 577.	0.8	17
841	Primary biliary cirrhosis: From bench to bedside. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2015, 6, 32.	0.6	11
842	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016, 16, e31681.	0.1	4
843	Rates of decompensation, hepatocellular carcinoma and mortality in AMA $\alpha$ -negative primary biliary cholangitis cirrhosis. <i>Liver International</i> , 2022, 42, 384-393.	1.9	7
844	Primary Biliary Cholangitis. , 2022, , 27-84.		0
845	Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. <i>Scientific Reports</i> , 2021, 11, 19705.	1.6	8
846	Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. <i>Cells</i> , 2021, 10, 2772.	1.8	4
847	Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 78, 227-234.	0.2	9
850	Nonneoplastic Hepatobiliary Disease. , 2011, , 1771-1827.		0
851	Cholestasis and Biliary Tract Disorders. , 2011, , 52-70.		1
852	Prolonged treatment with ursodeoxycholic acid of patients with primary biliary cirrhosis and their clinical course -Study Group for Urso-PBC Special Survey-. <i>Acta Hepatologica Japonica</i> , 2011, 52, 584-601.	0.0	0

#	ARTICLE	IF	CITATIONS
853	Managing the Patient with Features of Overlapping Autoimmune Liver Disease. , 2012, , 217-234.		0
855	Primary biliary cirrhosis and liver transplantation. Intractable and Rare Diseases Research, 2012, 1, 66-80.	0.3	10
860	Inflammatory hepatobiliary diseases. , 2013, , 910-921.		0
862	The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea. Korean Journal of Medicine, 2013, 84, 211.	0.1	2
863	The Diagnosis and Classification of Immune-Mediated Biliary Diseases. , 2014, , 111-122.		0
865	Overlap Syndromes. , 2014, , 317-329.		0
866	Complications of Cholestasis. Clinical Gastroenterology, 2014, , 163-188.	0.0	0
867	Diagnosis and UDCA Treatment of Primary Biliary Cirrhosis. , 2014, , 249-259.		0
868	Management of the Patients with Feature of Autoimmune Hepatitis. , 2014, , 277-286.		0
869	Hepatopatías autoinmunes: cirrosis biliar primaria, hepatitis autoinmune y colangitis esclerosante primaria. , 2014, , 50-55.		1
872	A case of hepatitis hard to diagnose autoimmune hepatitis or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Acta Hepatologica Japonica, 2014, 55, 360-366.	0.0	0
873	Liver Transplantation for Primary Biliary Cirrhosis. , 2014, , 287-300.		3
874	Optimal use of corticosteroids in gastroenterology and hepatology. Journal of Translational Internal Medicine, 2014, 2, 53-58.	1.0	2
875	PRIMARY BILIARY CIRRHOSIS ASSOCIATION WITH RHEUMATOID ARTHRITIS: A RARE CASE PRESENTATION. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 10117-10119.	0.1	0
876	A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature. Euroasian Journal of Hepato-gastroenterology, 2015, 5, 122-126.	0.1	1
878	Hepatobiliary Diseases. , 2016, , 253-266.		0
879	Cholestasis. Clinical Gastroenterology, 2016, , 141-142.	0.0	0
881	Cancer in Systemic Sclerosis. , 2017, , 525-532.		0



#	ARTICLE	IF	CITATIONS
882	Overlap Syndromes of Primary Sclerosing Cholangitis. , 2017, , 41-57.		0
883	Primary Biliary Cholangitis. In Clinical Practice, 2017, , 227-242.	0.1	0
884	Health Maintenance in Liver Disease and Cirrhosis. , 2017, , 89-98.		1
885	Autoimmune Liver Diseases: Primary Biliary Cholangitis. , 2017, , 251-287.		0
886	Autoimmune Liver Diseases: Overlap Syndromes. , 2017, , 307-328.		0
887	A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea. Korean Journal of Family Medicine, 2017, 38, 43.	0.4	0
888	Bile Acids and Cholestatic Liver Disease 1: Primary Biliary Cholangitis (PBC). , 2017, , 109-119.		0
889	Haut. , 2018, , 869-900.		0
890	Role of Nerve Growth Factor (NGF) and Its Receptor Tyrosine Kinase A (Trk A) in Egyptian Cirrhotic Patients with Pruritus. Open Journal of Gastroenterology, 2018, 08, 317-326.	0.1	0
891	Racial disparity in primary biliary cholangitis (pbc) patients seen in an urban academic gi clinic. Gastroenterology & Hepatology (Bartlesville, Okla ), 2018, 9, .	0.0	0
892	Risk stratification and treatment of primary biliary cholangitis. Revista Espanola De Enfermedades Digestivas, 2018, 111, 63-70.	0.1	1
893	Primary Biliary Cholangitis. , 2018, , 610-625.e3.		0
894	An adult case of primary biliary cholangitis accompanied by a patent ductus venosus showing type-I congenital absence of the portal vein. Acta Hepatologica Japonica, 2018, 59, 217-223.	0.0	0
895	Wouldn't Human Understanding be Necessary to Treat Patients with Pancreaticobiliary Disease More Effectively?. The Korean Journal of Pancreas and Biliary Tract, 2018, 23, 89-100.	0.0	0
897	Primary Biliary Cirrhosis and Ankylosing Spondylitis, A Rare Association. Medicina Interna (Bucharest,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
898	Role of regulatory T cells in pathogenesis and therapy of autoimmune liver disease. World Chinese Journal of Digestology, 2019, 27, 665-670.	0.0	0
899	The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis. Annals of Translational Medicine, 2019, 7, 389-389.	0.7	7
900	Â«GastroenterologicalÂ» rheumatology: differential diagnosis of early arthritis. Sovremennaya Revmatologiya, 2019, 13, 76-81.	0.1	1

#	ARTICLE	IF	CITATIONS
901	Seronegative Primary Biliary Cholangitis in a Middle Age Male- A Rare Entity. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 883-886.	0.0	0
902	Autoimmune Overlap Syndromes. , 2020, , 137-149.		0
903	Prospects of using biotechnology to improve morphofunctional state of liver. IOP Conference Series: Earth and Environmental Science, 0, 613, 012050.	0.2	0
904	Primary Biliary Cholangitis. , 2020, , 335-357.		1
905	Assessment of Liver Function. , 2020, , 407-426.		0
907	Diffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report. Annals of Dermatology, 2020, 32, 69.	0.3	0
908	Primary Biliary Cholangitis. , 2020, , 1149-1171.		1
909	Colestasis en el adulto: enfoque diagn3stico y terap3utico. Revisi3n de tema. Revista Colombiana De Gastroenterologia, 2020, 35, 76-86.	0.1	1
910	Early histopathologic changes in primary biliary cholangitis: does "minimal change" primary biliary cholangitis exist? A pathologist's view. European Journal of Gastroenterology and Hepatology, 2021, 33, e7-e12.	0.8	3
911	Primary biliary cholangitis: review for radiologists. Abdominal Radiology, 2023, 48, 127-135.	1.0	6
912	Non-tumoral Pathology of the Intrahepatic Biliary Tract. Medical Radiology, 2021, , 337-364.	0.0	0
913	Otoimm4n karaci4yer hastal4±4±nda oksidatif dengesizlik: oksidan-antioksidan durumun ve iskemi modifiye alb4minin de4erlendirilmesi. S4leyman Demirel 4eniversitesi T4p Fak4ltesi Dergisi, 0, , .	0.0	0
914	Keratin 19 and mesenchymal markers for evaluation of epithelial"mesenchymal transition and stem cell niche components in primary biliary cholangitis by sequential elution-stripping multiplex immunohistochemistry. Journal of Histotechnology, 2020, 43, 163-173.	0.2	3
915	Clinical significance of IgG antimitochondrialAM2 antibody levels in primary biliary cholangitis: A single center study from China. PLoS ONE, 2020, 15, e0242164.	1.1	2
917	Management of pruritus in patients with cholestatic liver disease. Gastroenterology and Hepatology, 2011, 7, 615-7.	0.2	6
918	A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian Journal of Medical Research, 2013, 137, 922-7.	0.4	18
919	Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2018, 14, 154-163.	0.2	7
920	Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting. Missouri Medicine, 2010, 107, 113-8.	0.3	4

#	ARTICLE	IF	CITATIONS
921	Use of Obeticholic Acid in Patients With Primary Biliary Cholangitis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 654-657.	0.2	2
922	Primary biliary cholangitis with contemporary presence of anti-mitochondrial and anti-rods and rings autoantibodies: literature first case. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019, 12, 76-82.	0.6	5
923	Evaluation of the effects of additional therapy with oxymel in patients with refractory primary sclerosing cholangitis and primary biliary cholangitis: A quasi-experimental study. <i>Avicenna Journal of Phytomedicine</i> , 2021, 11, 154-167.	0.1	0
925	The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. <i>Digestive and Liver Disease</i> , 2022, 54, 1094-1100.	0.4	4
926	QTc interval prolongation in the patients with primary biliary cholangitis. <i>Annals of Noninvasive Electrocardiology</i> , 2022, 27, e12925.	0.5	3
927	Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. <i>Revista De GastroenterologÁa De MÃ©xico (English Edition)</i> , 2021, 87, 80-80.	0.1	0
928	Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. <i>Minerva Medica</i> , 2023, 113, .	0.3	11
929	New agents for immunosuppression. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 54-55, 101763.	1.0	2
930	Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis. <i>Disease Markers</i> , 2022, 2022, 1-7.	0.6	3
931	Characterization of the Pathology, Biochemistry, and Immune Response in Kunming (KM) Mice Following <i>Fasciola gigantica</i> Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 793571.	1.8	4
932	Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway. <i>Pharmaceuticals</i> , 2022, 15, 107.	1.7	3
933	The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 136-143.	1.0	5
934	Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 681.	1.0	0
935	Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases. <i>Journal of Translational Autoimmunity</i> , 2022, 5, 100145.	2.0	16
936	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. <i>Hepatology International</i> , 2022, 16, 1-23.	1.9	45
939	Haut. , 2022, , 961-996.		0
940	Autoimmunity overlaps primary biliary cirrhosis: a not straightforward diagnosis. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2022, 68, 139-141.	0.3	0
941	Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease. <i>Frontiers in Immunology</i> , 2022, 13, 822996.	2.2	5

#	ARTICLE	IF	CITATIONS
942	Immunoglobulin M: A Neglected Serum Biomarker in Treatment- Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase. <i>Hepatology Communications</i> , 2022, 6, 1403-1412.	2.0	3
943	The Role of Autoantibody Testing in Modern Personalized Medicine. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 251-288.	2.9	3
944	Pregnancy in women with liver cirrhosis is associated with increased risk for complications: A systematic review and meta-analysis of the literature. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1644-1652.	1.1	7
945	Effect of LncRNA XIST on Immune Cells of Primary Biliary Cholangitis. <i>Frontiers in Immunology</i> , 2022, 13, 816433.	2.2	6
946	The latest research trends in primary biliary cholangitis: a bibliometric analysis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 347-355.	1.9	2
947	Naturally-derived endoplasmic reticulum stress inhibitors for osteoarthritis?. <i>European Journal of Pharmacology</i> , 2022, 922, 174903.	1.7	8
948	Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e197-e205.	0.8	4
950	The NOD Mouse Beyond Autoimmune Diabetes. <i>Frontiers in Immunology</i> , 2022, 13, 874769.	2.2	20
951	Disease Monitoring Parameters for Autoimmune Diseases. <i>Asian Pacific Journal of Health Sciences</i> , 2021, 8, 24-31.	0.0	1
953	Primary Biliary Cholangitis with Ankylosing Spondylitis. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2022, 79, 270-273.	0.2	1
954	Clinical Patterns of Primary Biliary Cholangitis: Comparison Between Two European Case Series. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 136-142.	0.4	1
955	Mechanism for development of malnutrition in primary biliary cholangitis. <i>World Journal of Meta-analysis</i> , 2022, 10, 81-98.	0.1	4
956	Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis. <i>Biomedicines</i> , 2022, 10, 1694.	1.4	2
957	PPAR $\alpha$ : A potential therapeutic target of cholestasis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
959	Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
960	Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 647-659.	3.3	11
961	Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000857.	1.1	1
962	Macrophage polarization is involved in liver fibrosis induced by $\beta$ -adrenoceptor autoantibody. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1100-1112.	0.9	2

#	ARTICLE	IF	CITATIONS
963	Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China. <i>World Journal of Gastroenterology</i> , 2022, 28, 4417-4430.	1.4	2
964	Circulating extracellular vesicle-encapsulated microRNA-557 induces a proinflammatory immune response and serves as a diagnostic or relapse marker in autoimmune hepatitis. <i>Hepatology Research</i> , 2022, 52, 1034-1049.	1.8	3
965	Primary biliary cholangitis presenting with Fanconi syndrome: an important phenotype. <i>BMJ Case Reports</i> , 2022, 15, e248461.	0.2	1
966	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114742.	2.6	1
967	A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211141.	1.1	7
968	Nicht-alkoholische Fettlebererkrankung als Komorbidität chronischer Lebererkrankungen. , 2022, , 301-309.		0
969	The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
970	LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1587.	1.1	3
971	The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	7
974	Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2022, 6, 3487-3495.	2.0	8
975	Mechanisms of pruritus in cholestasis: understanding and treating the itch. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 26-36.	8.2	16
976	Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions. <i>Rheumatology &amp; Autoimmunity</i> , 0, , .	0.3	0
977	Advances in understanding the regulatory mechanism of organic solute transporter $\text{OAT}^1$ . <i>Life Sciences</i> , 2022, 310, 121109.	2.0	3
978	Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
979	Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 241-251.	0.4	3
980	Pathologic features and differential diagnosis of chronic hepatitis. <i>Diagnostic Histopathology</i> , 2023, 29, 12-22.	0.2	1
981	Current trends and future perspectives in the treatment of PBC and PSC: A review. <i>Health Sciences Review</i> , 2022, , 100065.	0.6	0
982	Diagnostic value of screening methods for the determination of antinuclear antibodies using indirect immunofluorescence on HEp-2 cells and enzyme immunoassay in autoimmune liver diseases. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2022, 67, 652-657.	0.2	0

#	ARTICLE	IF	CITATIONS
983	Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. <i>Biomedicines</i> , 2022, 10, 3046.	1.4	5
984	Automated Machine Learning in Predicting 30-Day Mortality in Patients with Non-Cholestatic Cirrhosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1930.	1.1	2
985	Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1559.	1.8	4
986	An Assessment of the Serum Activity of ADH and ALDH in Patients with Primary Biliary Cholangitis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	1
987	Challenges for diagnosis and treatment of primary biliary cholangitis. , 2023, , 215-241.		0
988	Murine breast cancers disorganize the liver transcriptome in a zoned manner. <i>Communications Biology</i> , 2023, 6, .	2.0	4
990	Non-Neoplastic Disorders of the Liver. , 2024, , 489-556.		0
991	Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	4
992	<scp>CCL26</scp> in primary biliary cholangitis â€œ Is it a novel disease mediator?. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 648-656.	0.9	0
993	Immune thrombocytopenic purpura in primary biliary cholangitis and localized cutaneous systemic sclerosis: case report and literature review. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
994	Dyslipidemia and its features in primary biliary cholangitis. <i>Zdravoohranenie TadÅ¼ikistana</i> , 2023, , 119-130.	0.2	0
995	Zero Mortality in Living-Donor Liver Transplantation for Primary Biliary Cholangitis in Patients With a Meld Score of &lt;20. <i>Transplantation Proceedings</i> , 2023, , .	0.3	0
1013	Cholestasis and Biliary Tract Disorders. , 2024, , 74-100.e4.		0
1015	Osteoporosis and Chronic Liver Disease. , 2023, , 1-16.		0
1018	Laboratory Diagnostics in Autoimmune Diseases. , 2023, , 489-500.		0